What happens if sentinel node biopsy is positive

If you’ve been diagnosed with breast cancer or melanoma, your doctor may have told you that the cancer could spread to nearby lymph nodes and from there, to other, more distant, parts of the body.

It’s important for your doctor to know if the cancer has spread so that he or she can formulate the best course of treatment for you. To do this, your doctor might recommend that you undergo a surgical procedure called a sentinel lymph node biopsy (SLNB).

In this procedure, a surgeon removes one, or in some cases, a few sentinel lymph nodes—the lymph nodes to which cancer first spreads—near the site of the original tumor. For a patient with breast cancer, for instance, the surgeon will remove lymph nodes in the armpit closest to the affected breasts. The lymph nodes are then examined to check for the presence of cancer cells.

In the past, before SLNB was in use, to determine whether cancer had spread to the lymph nodes, surgeons typically removed nearly all of the lymph nodes near the site of the cancer. This subjected patients to a major surgery with a substantial risk for long-term complications.

But today, doctors can use SLNB to accurately determine if cancer has spread without the need for major surgery and the risks that come with it.

Adults have hundreds of small, bean-shaped structures called lymph nodes spread throughout the body. Among other places, clusters of lymph nodes are found in the armpit, neck, abdomen, groin, and chest.

Each of these lymph nodes is part of the lymphatic system, a network of vessels that drains a colorless fluid called lymph away from the body’s tissues and into the bloodstream. The system is crucial to maintaining fluid balance in the body.

Lymph is made up of various substances including water, cells of the immune system, waste products, and sometimes outside invaders like viruses or bacteria. It can also contain cancer cells.

Before lymph reaches the bloodstream, it passes through the lymph nodes. The lymph nodes play a critical role: They filter out waste products, viruses, bacteria, and if they are present, cancer cells. The immune system kills many of the cancer cells that reach the lymph nodes. But some cancer cells may escape and migrate to other lymph nodes or even to distant parts of the body.

When cancer cells spread from some types of tumors, they migrate to nearby lymph nodes. For example, when certain types of breast cancer spreads, cancer cells frequently move to the lymph nodes in the armpit (where there are 20 to 30 lymph nodes) before spreading to other parts of the body.

But the cancer cells do not reach each of these lymph nodes simultaneously. That’s because the lymph nodes are organized in such a way that the cancer cells reach one lymph node, or sometimes a few lymph nodes, before moving on to the others. The lymph nodes to which cancer cells first spread are known as sentinel lymph nodes.

Doctors make decisions on how to best treat cancer patients based on several factors, including whether the cancer has spread to the lymph nodes.

One way of determining whether certain types of cancer have begun to spread is via SLNB. Before performing this surgical procedure, the surgeon must first identify the sentinel lymph nodes. 

To do this, a small amount of radioactive material, a blue dye, or both are injected into the tissue near the primary tumor. These substances drain through the lymphatic vessels and into nearby lymph nodes. The first node into which the injected substances drain is the sentinel lymph node.

If radioactive dye was injected, the surgeon will use a radiation-detecting device (like a Geiger counter) to locate the sentinel lymph node. If blue dye was injected, the sentinel lymph node will be stained blue, which allows the surgeon to locate it. 

The surgeon then removes the sentinel node through a small incision. (He or she may remove more than one lymph node if there are two or more sentinel lymph nodes.) After the sentinel lymph nodes are removed, a pathologist examines them under a microscope to see if they contain cancer cells.

If cancer cells are present (a “positive” biopsy result), then the surgeon may remove the remaining lymph nodes from the area and further testing is necessary to determine whether the cancer has spread beyond the lymph nodes. In some cases, instead of removing all remaining lymph nodes, doctors may proceed with radiation therapy, chemotherapy, and other cancer therapies or opt to monitor the status of the remaining lymph nodes. Monitoring may involve physical exams, imaging studies, or other tests.

If no cancer cells are detected (a “negative” biopsy result), then it is unlikely that the cancer has spread to the lymph nodes. In this case, it is not necessary to remove the remaining lymph nodes.

In most cases, side effects are minor and short-lived. They may include bruising, pain, numbness, discomfort, swelling, or bleeding at the incision site. In some cases, SLNB can cause a seroma, which is a buildup of fluid at the site of the surgery. If the surgeon injected blue dye for the procedure, it may be visible under the skin for two to three months (or longer) and urine may look bluish for the first day or two after the procedure.

In some cases, after a SLNB, the ability of the remaining lymph nodes to effectively drain fluid from nearby tissues is impaired. This may result in a long-term condition called lymphedema, which is characterized by the swelling of the tissues around the site of surgery. 

For instance, if SLNB is performed on the lymph nodes in an armpit, the lymphedema may cause the tissues in the arm to swell. Around 6% of women with breast cancer who undergo SLNB of lymph nodes in an armpit and 1% of people with melanoma who undergo SLNB develop lymphedema.

Other long-term complications that may result from SLNB include numbness near the biopsy site. People who undergo SLNB of the lymph nodes in the armpit, may have problems with shoulder movement and a reduced range of motion.

Last medically reviewed by Melanie Lynch, MD in March 2022.

  • Bladder Cancer, Brain and Other Nervous System Cancers, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma

    • Ages18 years and older
    • GenderBoth
    • Date05/27/2022

1. Bray F, Ferlay J, Soerjomataram I et al.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; : 394–424. [PubMed] [Google Scholar]

2. DeSantis CE, Ma J, Goding Sauer A et al.. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; : 439–448. [PubMed] [Google Scholar]

3. National Institute for Health and Care Excellence Advanced Breast Cancer: Diagnosis and Treatment. Clinical Guideline CG81. London: NICE; 2009. (updated 2017). [Google Scholar]

4. Weigelt B, Peterse JL, Van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; : 591–602. [PubMed] [Google Scholar]

5. LH Sobin MG, CH Wittekind. TNM Classification of Malignant Tumours, 7th ed Chichester: John Wiley and Sons; 2009. [Google Scholar]

6. Senkus E, Kyriakides S, Ohno S et al.. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; : v8–v30. [PubMed] [Google Scholar]

7. Kennecke H, Yerushalmi R, Woods R et al.. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; : 3271–3277. [PubMed] [Google Scholar]

8. Barter S BP. Breast Cancer. London: The Royal College of Radiologists; 2014. [Google Scholar]

9. American Society of Clinical Oncology Don’t perform PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis. Choosing Wisely 4 April 2019. https://www.choosingwisely.org/clinician-lists/american-society-clinical-oncology-pet-ct-radionuclide-bone-scans-in-staging-early-breast-cancer (cited March 2020).

10. National Institute for Health and Care Excellence Early and Locally Advanced Breast Cancer: Diagnosis and Management. NICE Guideline NG101. London: NICE; 2018. [Google Scholar]

11. Barrett T, Bowden D, Greenberg D et al.. Radiological staging in breast cancer: which asymptomatic patients to image and how. Br J Cancer 2009; : 1522–1528. [PMC free article] [PubMed] [Google Scholar]

12. Del Turco MR, Palli D, Cariddi A et al.. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA 1994; : 1593–1597. [PubMed] [Google Scholar]

13. Myers RE, Johnston M, Pritchard K et al.. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001; : 1439–1444. [PMC free article] [PubMed] [Google Scholar]

14. Chand N, Cutress R, Oeppen R et al.. Staging investigations in breast cancer: collective opinion of UK breast surgeons. Int J Breast Cancer 2013; : 506172. [PMC free article] [PubMed] [Google Scholar]

15. Veronesi U, Paganelli G, Viale G et al.. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; : 546–553. [PubMed] [Google Scholar]

16. Krag DN, Anderson SJ, Julian TB et al.. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; : 881–888. [PubMed] [Google Scholar]

17. POSNOC POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. http://www.posnoc.co.uk/healthcare-professionals/protocol.aspx (cited March 2020).

18. Purushotham A, Shamil E, Cariati M et al.. Age at diagnosis and distant metastasis in breast cancer–a surprising inverse relationship. Eur J Cancer 2014; : 1697–1705. [PubMed] [Google Scholar]

19. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; : 181–187. [PubMed] [Google Scholar]

20. Rosen PP, Groshen S, Saigo PE et al.. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; : 1239–1251. [PubMed] [Google Scholar]

21. Breast Cancer Clinical Expert Group Clinical Advice to Cancer Alliances for the Provision of Breast Cancer Services. 2017. https://breastcancernow.org/get-involved/campaign-us/what-we-think/clinical-advice-cancer-alliances-provision-breast-cancer (cited March 2020).

22. Aebi S, Davidson T, Gruber G et al.. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; : vi12–vi24. [PubMed] [Google Scholar]

23. Pellet AC, Erten MZ, James TA. Value analysis of postoperative staging imaging for asymptomatic, early-stage breast cancer: implications of clinical variation on utility and cost. Am J Surg 2016; : 1084–1088. [PubMed] [Google Scholar]

24. Solomayer E-F, Diel I, Meyberg G et al.. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000; : 271–278. [PubMed] [Google Scholar]

25. National Institute for Health and Care Excellence Improving Supportive and Palliative Care for Adults with Cancer. Cancer Service Guideline CSG 4. London: NICE; 2004. [Google Scholar]

26. Salhab M, Patani N, Mokbel K. Sentinel lymph node micrometastasis in human breast cancer: an update. Surg Oncol 2011; : e195–e206. [PubMed] [Google Scholar]

27. Reed J, Rosman M, Verbanac KM et al.. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009; : 333–340. [PubMed] [Google Scholar]


Page 2

Patient, tumour and axillary lymph node characteristics. Patients who had radiological staging (St) are compared with those that did not have radiological staging at presentation (NSt). Patients who had radiological staging and found to have distant metastasis at presentation (DMp) are compared with patients who had radiological staging and did not have distant metastasis (NDMp). Ordinal data described as number of patients with percentages in parentheses, continuous data as mean (± standard deviation, SD). Not significant (NS; p > 0.05). Significance set at p < 0.05%.

St (n = 227)NSt (N = 103)p-valueDMp (n = 8)NDMp (N = 219)p-value
Patient characteristics:
 Mean age (years)60 (± 13)66 (± 15)0.00156 (± 12)60 (± 13)NS
 Female sex224 (99%)101 (98%)NS8 (100%)216 (99%)NS
Route of referral:
 Symptomatic 156 (68%)70 (68%)NS6 (75%)150 (68%)NS
 Screening 71 (32%)33 (32%)NS2 (25%)69 (32%)NS
Breast tumour characteristics:
 Multifocal tumours61 (27%)19 (18%)NS3 (38%)58 (27%)NS
Invasive grade:
 Well differentiated22 (10%)13 (12%)NS0(0%)22 (10%)NS
 Moderately differentiated131 (58%)60 (58%)NS3 (38%)128 (58%)NS
 Poorly differentiated67 (29%)25 (24%)NS5(62%)62 (28%)0.037
Associated with ductal carcinoma in situ169 (74.4%)75 (72%)NS7 (87%)162 (74%)NS
 Low grade7 (3%)12 (11%)NS0 (0%)7 (3%)NS
 Medium grade70 (30%)26 (25%)NS1 (12%)69 (31%)NS
 High grade92 (40.5%)37 (35%)NS6 (75%)86 (39%)0.043
Receptor status:
 ER/PR+, HER2–194 (85%)88 (85%)NS7 (87.5%)187 (85%)NS
 ER/PR+, HER2+18 (8%)10 (10%)NS018 (8%)NS
 ER/PR–, HER2+1 (0.4%)2 (2%)NS01 (0.5%)NS
 ER/PR–, HER2– (triple negative)14 (6%)3 (3%)NS1 (12.5%)13 (6%)NS
Mean invasive tumour size (mm)24 (± 15)23 (± 14)NS37.7 (± 19)23.9 (± 15)0.014
Mean whole tumour size (mm)30 (± 18)27 (± 16)NS42(± 16)29.6 (± 18)NS
Lymphovascular invasion111 (48%)33 (32%)0.0045 (62%)106 (48%)NS
Axillary characteristics:
 Macrometastasis210 (92%)27 (26%)< 0.0018 (100%)202 (92%)NS
 Micrometastasis17 (7%)75 (72%)< 0.0010 (0%)17 (8%)NS
 Mean number of +ve sentinel lymph node biopsies1.4 (± 0.8)1.08 (± 0.4)< 0.0011.8 (± 0.7)1.45 (± 0.8)NS
Survival characteristics:
 All-cause mortality13 (5.7%)13 (12.6%)0.0313 (37%)10 (4.6%)< 0.001
 Disease-specific mortality9 (3.9%)3 (2.9%)NS3 (37%)6 (2.7%)< 0.001
Length of follow-up (months)58 (± 15)45 (± 18)NS40 (± 20)48 (± 15)NS